Pharmacogenomics Journal

Papers
(The median citation count of Pharmacogenomics Journal is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study87
Development of an extensive workflow for comprehensive clinical pharmacogenomic profiling: lessons from a pilot study on 100 whole exome sequencing data49
Correction to: A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform36
Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study32
STRIPE partners in precision medicine series: provider perspective24
Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study23
A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidone19
Extreme phenotype sampling and next generation sequencing to identify genetic variants associated with tacrolimus in African American kidney transplant recipients13
Using ChatGPT to predict the future of personalized medicine13
Effects and interaction of single nucleotide polymorphisms at the pharmacokinetic/pharmacodynamic site: insights from the Rotterdam study into metformin clinical response and dose titration13
A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care13
Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder12
STRIPE partners in precision medicine series: Patient perspective10
The organoid as reliable cancer modeling in personalized medicine, does applicable in precision medicine of head and neck squamous cell carcinoma?10
Investigating genetic variants for treatment response to selective serotonin reuptake inhibitors in syndromal factors and side effects among patients with depression in Taiwanese Han population10
Sequencing of genes of drug response in tumor DNA and implications for precision medicine in cancer patients10
TMEM158, as plasma cfRNA marker, promotes proliferation and doxorubicin resistance in ovarian cancer9
APF2: an improved ensemble method for pharmacogenomic variant effect prediction9
Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing9
Pharmacogenomics to optimise psychotropic prescribing: a survey of mental health professionals’ perceptions, knowledge, and educational needs8
CYP2C19 point-of-care testing: where are we now and where should we go?8
Inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppress7
Clinical and economic outcomes of a pharmacogenomics-enriched comprehensive medication management program in a self-insured employee population7
Knowledge and attitudes of medical and pharmacy students about pharmacogenomics: a systematic review and meta-analysis7
Combined Role of CYP3A4 and CYP3A5 genetic variants in tacrolimus dose-adjusted trough levels: a clinical retrospective study in kidney transplant patients6
Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects6
Network pharmacology prediction, molecular docking and in vitro experiment explored the potential mechanism of Gaoyuan’an capsule in improving hypoxia tolerance6
Genetic markers of early response to lurasidone in acute schizophrenia6
Targeted next-generation sequencing of genes involved in Warfarin Pharmacodynamics and pharmacokinetics pathways using the Saudi Warfarin Pharmacogenetic study (SWAP)6
Assessment of clinically actionable pharmacogenetic markers to stratify anti-seizure medications6
Potential of pharmacogenetics in treatment of chronic inflammatory diseases – a danish report overview from 2000 – 20246
The role of cytochrome P450 polymorphisms in the pharmacokinetics of oral esketamine6
Use of medications with pharmacogenomic guidelines and adverse outcomes in hospitalised older patients: a retrospective cross-sectional study5
Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy5
Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn’s disease patients5
An innovative model for pharmacogenomics critical results identification and intervention5
Polygenic score analyses on antidepressant response in late-life depression, results from the IRL-GRey study5
A blockchain-based framework to support pharmacogenetic data sharing5
Nimodipine-associated standard dose reductions and neurologic outcomes after aneurysmal subarachnoid hemorrhage: the era of pharmacogenomics5
Bioinformatics driven discovery of small molecule compounds that modulate the FOXM1 and PPARA pathway activities in breast cancer5
Cost-effectiveness of genotype-guided acenocoumarol therapy in atrial fibrillation: a pharmacogenomic simulation study in the chilean population5
Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci5
Influence of genetic biomarkers on cardiac diseases in childhood cancer survivors: a systematic review5
Benchmarking large language models for replication of guideline-based PGx recommendations4
Non-steroidal anti-inflammatory drug target gene associations with major depressive disorders: a Mendelian randomisation study integrating GWAS, eQTL and mQTL Data4
STRIPE partners in precision medicine: regulatory perspective4
Association of pharmacodynamic genes with treatment outcomes in major depressive disorder: results from a Sardinian cohort4
Implementation of pharmacogenetic testing in pediatric oncology: barriers and facilitators assessment at eight Canadian academic health centres4
Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis4
The association between the number of HLA risk alleles and drug allergy and its implications for HLA screening – a case-control study4
Genome-wide screening of pharmacogenomic biomarkers in jordanian patients with genetic disorders4
DNA polymerase gamma variants and hepatotoxicity during maintenance therapy of childhood acute lymphoblastic leukemia: is there a causal relationship?3
Utilisation of drugs with pharmacogenetic recommendations in children in Switzerland3
Influence of combined CYP2C19 and CYP2D6 phenotypes on adverse drug reactions in patients with major depressive disorder: a clinical cohort study3
Exploring pharmacogenetic factors influencing hydroxyurea response in tanzanian sickle cell disease patients: a genomic medicine approach3
Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone3
The interplay between SLC6A4 and HTR1A genetic variants that may lead to antidepressant failure3
Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug3
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)3
Implementing CYP2C19-guided clopidogrel therapy: a scoping review of pharmacogenomic testing services3
Computational variant predictors for pharmacogenomics: from evaluation of single alleles to assessment of adverse drug reactions to antidepressants2
Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?2
Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?2
Economic effectiveness of pharmacogenomics-guided prescribing for psychiatric disorders: a systematic review and meta-analysis2
Pharmacogenomic study—A pilot study of the effect of pharmacogenomic phenotypes on the adequate dosing of verapamil for migraine prevention2
Protein network and pathway analysis in a pharmacogenetic study of cyclosporine treatment response in Greek patients with psoriasis2
SLCO1B1*5 is protective against non-senile cataracts in cohort prescribed statins: analysis in a British-South Asian cohort2
Cytochrome P450-2D6 activity in people with codeine use disorder2
Opioid use disorder risk alleles in self-reported assigned African American/Afro-Caribbean and European biogeographical genetic ancestry groups and in males and females2
Publisher Correction: Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data2
Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis2
STRIPE partners in precision medicine series: pharmacist perspective2
0.049286127090454